Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Current Signal: SELL (auto-tracking)
-6.26% $16.47
America/New_York / 24 apr 2024 @ 16:00
FUNDAMENTALS | |
---|---|
MarketCap: | 820.71 mill |
EPS: | -1.820 |
P/E: | -9.05 |
Earnings Date: | May 01, 2024 |
SharesOutstanding: | 49.83 mill |
Avg Daily Volume: | 0.987 mill |
RATING 2024-04-24 |
---|
C+ |
Sell |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Sell | |
Return On Equity: | Sell | |
Return On Asset: | Sell | |
DE: | Neutral | |
P/E: | Strong Sell | |
Price To Book: | Buy |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
Revenue | ||||||
Gr.Profit | ||||||
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -9.05 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-1.54x |
Company: PE -9.05 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$-12.07 (-173.26%) $-28.54 |
Date: 2024-04-24 |
Expected Trading Range (DAY) |
---|
$ 15.09 - 17.85 ( +/- 8.40%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-18 | Adage Capital Management, L.p. | Buy | 0 | Common Stock, par value $0.001 per share ("Common Stock") |
2024-04-18 | Cormorant Asset Management, Lp | Buy | 186 521 | Common Stock |
2024-04-18 | Cormorant Asset Management, Lp | Buy | 395 244 | Common Stock |
2024-03-30 | Paggiarino Dario A. | Buy | 14 000 | Common Stock |
2024-03-30 | Paggiarino Dario A. | Buy | 30 570 | Common Stock |
INSIDER POWER |
---|
41.04 |
Last 98 transactions |
Buy: 1 049 923 | Sell: 467 144 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 | |
MACD |
Volume Signals | |
---|---|
Price | $16.47 (-6.26% ) |
Volume | 1.084 mill |
Avg. Vol. | 0.987 mill |
% of Avg. Vol | 109.81 % |
Signal 1: | |
Signal 2: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $29.68 | N/A | Active |
---|
EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema; YUTIQ, a fluocinolone acetonide intravitreal implant for intravitreal injection for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye; and DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the treatment of wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion; and YUTIQ50 for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The company has strategic collaborations with Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. It also has a commercial alliance with ImprimisRx PA, Inc. for the joint promotion of DEXYCU for the treatment of post-operative inflammation following ocular surgery. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts.